Global Information
회사소개 | 문의 | 비교리스트

세계의 항체약물접합체 시장 : 작용기서별, 약제별, 기술별, 용도별, 최종사용자별, 지역별 예측(-2027년) - COVID-19의 누적적 영향

Antibody Drug Conjugate Market Research Report by Mechanism of Action, by Drugs, by Technology, by Application, by End User, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

리서치사 360iResearch LLP
발행일 2022년 01월 상품 코드 1045224
페이지 정보 영문 209 Pages
가격
US $ 3,949 ₩ 4,800,000 Online Access (Single User License - 1 Year)
US $ 4,949 ₩ 6,016,000 PDF (Single User License) + Excel
US $ 5,949 ₩ 7,231,000 PDF (1-5 User License) + Excel
US $ 7,949 ₩ 9,662,000 PDF (Site License) + Excel
US $ 9,949 ₩ 12,094,000 PDF (Enterprise License) + Excel


세계의 항체약물접합체 시장 : 작용기서별, 약제별, 기술별, 용도별, 최종사용자별, 지역별 예측(-2027년) - COVID-19의 누적적 영향 Antibody Drug Conjugate Market Research Report by Mechanism of Action, by Drugs, by Technology, by Application, by End User, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
발행일 : 2022년 01월 페이지 정보 : 영문 209 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 항체약물접합체 시장 규모는 2020년에 37억 8,523만 달러를 기록하고 2021년에는 43억 7,875만 달러에 달할 전망이며, 이후 16.04%의 CAGR로 추이하고 2027년까지 107억 2,758만 달러에 달할 것으로 예상되고 있습니다.

세계의 항체약물접합체 시장에 대해 조사했으며, 시장의 기회 및 과제, 촉진 및 억제요인, COVID-19의 누적적 영향, 작용기서별·약제별·기술별·용도별·최종사용자별·지역별 시장 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서문

  • 조사의 목적
  • 시장 세분화와 범위
  • 조사 대상 기간
  • 통화와 가격
  • 언어
  • 제한사항
  • 전제조건
  • 이해관계자

제2장 조사 방법

  • 정의 : 조사 목적
  • 결정 : 조사 계획
  • 준비 : 조사 기기
  • 수집 : 데이터 소스
  • 분석 : 데이터 해석
  • 책정 : 데이터 검증
  • 공개 : 조사 리포트
  • 반복 : 리포트 업데이트

제3장 개요

제4장 시장 개요

제5장 시장 인사이트

  • 시장 역학
    • 촉진요인
    • 억제요인
    • 시장 기회
    • 과제
  • COVID-19의 누적적 영향

제6장 항체약물접합체 시장 : 작용기서별

  • CD30 항체
  • HER2 항체

제7장 항체약물접합체 시장 : 약제별

  • Adcetris
  • Kadcyla

제8장 항체약물접합체 시장 : 기술별

  • Cleavable Linker
  • Linkerless
  • Non-cleavable Linker

제9장 항체약물접합체 시장 : 용도별

  • 혈액암
  • 유방암
  • 백혈병
  • 림프종
  • 다발성 골수종
  • 요로상피암·방광암

제10장 항체약물접합체 시장 : 최종사용자별

  • 학술조사기관
  • 바이오제약 기업
  • 바이오테크놀러지 기업
  • 병원
  • 기타
  • 전문암센터

제11장 아메리카의 항체약물접합체 시장

  • 아르헨티나
  • 브라질
  • 캐나다
  • 멕시코
  • 미국

제12장 아시아태평양의 항체약물접합체 시장

  • 호주
  • 중국
  • 인도
  • 인도네시아
  • 일본
  • 말레이시아
  • 필리핀
  • 싱가포르
  • 한국
  • 대만
  • 태국

제13장 유럽, 중동·아프리카의 항체약물접합체 시장

  • 프랑스
  • 독일
  • 이탈리아
  • 네덜란드
  • 카타르
  • 러시아
  • 사우디아라비아
  • 남아프리카공화국
  • 스페인
  • 아랍에미리트
  • 영국

제14장 경쟁 구도

  • FPNV 포지셔닝 매트릭스
    • 상한
    • 사업 전략
    • 제품 만족도
  • 시장 순위 분석
  • 시장 점유율 분석 : 주요 기업별
  • 경쟁 시나리오
    • 합병·인수
    • 합의, 협업 및 파트너십
    • 신제품 발매와 강화
    • 투자와 자금조달
    • 평가, 인지, 확대

제15장 기업의 유저빌리티 개요

  • Abbvie Inc.
  • ADC Therapeutics
  • Agensys, Inc.
  • Astellas Pharma
  • AstraZeneca
  • Bayer AG
  • Celldex Therapeutics Inc.
  • Concortis Biotherapeutics
  • Daiichi Sankyo Company Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Immunomedics Inc.
  • Novartis AG
  • Oxford BioTherapeutics
  • Pfizer, Inc.
  • Sanofi S.A.
  • Seagen, Inc.
  • Seattle Genetics Inc.
  • Synthon Holding B.V.
  • Takeda Pharmaceutical Company Ltd.

제16장 부록

  • 디스커션 가이드
  • 라이선스와 가격
KSA 22.01.14

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: MARKET DYNAMICS
  • FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2027 (%)
  • FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2020 VS 2027 (USD MILLION)
  • FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2027
  • FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, 2018-2027 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2 ANTIBODIES, 2018-2027 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2 ANTIBODIES, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2020 VS 2027 (%)
  • FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2020 VS 2027 (USD MILLION)
  • FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2027
  • FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, 2018-2027 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, 2018-2027 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2020 VS 2027 (%)
  • FIGURE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2020 VS 2027 (USD MILLION)
  • FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2027
  • FIGURE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, 2018-2027 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, 2018-2027 (USD MILLION)
  • FIGURE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, 2018-2027 (USD MILLION)
  • FIGURE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2020 VS 2027 (%)
  • FIGURE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2020 VS 2027 (USD MILLION)
  • FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2027
  • FIGURE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, 2018-2027 (USD MILLION)
  • FIGURE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2027 (USD MILLION)
  • FIGURE 32. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 33. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LEUKEMIA, 2018-2027 (USD MILLION)
  • FIGURE 34. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LEUKEMIA, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 35. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, 2018-2027 (USD MILLION)
  • FIGURE 36. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 37. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2027 (USD MILLION)
  • FIGURE 38. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 39. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, 2018-2027 (USD MILLION)
  • FIGURE 40. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 41. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2020 VS 2027 (%)
  • FIGURE 42. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2020 VS 2027 (USD MILLION)
  • FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2027
  • FIGURE 44. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2027 (USD MILLION)
  • FIGURE 45. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 46. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2027 (USD MILLION)
  • FIGURE 47. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 48. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2027 (USD MILLION)
  • FIGURE 49. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 50. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2027 (USD MILLION)
  • FIGURE 51. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 52. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY OTHERS, 2018-2027 (USD MILLION)
  • FIGURE 53. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY OTHERS, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 54. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, 2018-2027 (USD MILLION)
  • FIGURE 55. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2020 VS 2027 (USD MILLION)
  • FIGURE 56. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 57. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 58. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 59. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 60. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 61. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 62. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 63. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 64. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 65. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 66. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 67. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 68. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 69. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 70. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 71. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 72. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 73. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 74. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 75. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 76. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 77. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 78. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 79. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 80. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 81. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 82. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 83. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 84. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 85. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • FIGURE 86. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: FPNV POSITIONING MATRIX
  • FIGURE 87. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 88. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIBODY DRUG CONJUGATE MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2027 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2 ANTIBODIES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2027 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY OTHERS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 27. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 28. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 29. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 30. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 31. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 32. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 34. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 35. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 36. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 37. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 38. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 39. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 40. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 41. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 42. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 43. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 44. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 45. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 46. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 47. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 48. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 49. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 50. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 51. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 52. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 53. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 54. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 55. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 56. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: SCORES
  • TABLE 58. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: BUSINESS STRATEGY
  • TABLE 59. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: PRODUCT SATISFACTION
  • TABLE 60. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: RANKING
  • TABLE 61. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 62. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: MERGER & ACQUISITION
  • TABLE 63. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 64. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 65. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: INVESTMENT & FUNDING
  • TABLE 66. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 67. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: LICENSE & PRICING

The Global Antibody Drug Conjugate Market size was estimated at USD 3,785.23 million in 2020 and expected to reach USD 4,378.75 million in 2021, at a CAGR 16.04% to reach USD 10,727.58 million by 2027.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2027 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Antibody Drug Conjugate to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Mechanism of Action, the market was studied across CD30 Antibodies and HER2 Antibodies.
  • Based on Drugs, the market was studied across Adcetris and Kadcyla.
  • Based on Technology, the market was studied across Cleavable Linker, Linkerless, and Non-cleavable Linker.
  • Based on Application, the market was studied across Blood Cancer, Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma, and Urothelial Cancer & Bladder Cancer.
  • Based on End User, the market was studied across Academic Research Institutes, Biopharmaceutical Companies, Biotechnology Companies, Hospitals, Others, and Specialized Cancer Centers.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antibody Drug Conjugate Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antibody Drug Conjugate Market, including Abbvie Inc., ADC Therapeutics, Agensys, Inc., Astellas Pharma, AstraZeneca, Bayer AG, Celldex Therapeutics Inc., Concortis Biotherapeutics, Daiichi Sankyo Company Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Immunomedics Inc., Novartis AG, Oxford BioTherapeutics, Pfizer, Inc., Sanofi S.A., Seagen, Inc., Seattle Genetics Inc., Synthon Holding B.V., and Takeda Pharmaceutical Company Ltd..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Antibody Drug Conjugate Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antibody Drug Conjugate Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antibody Drug Conjugate Market?
  • 4. What is the competitive strategic window for opportunities in the Global Antibody Drug Conjugate Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Antibody Drug Conjugate Market?
  • 6. What is the market share of the leading vendors in the Global Antibody Drug Conjugate Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Antibody Drug Conjugate Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Define: Research Objective
  • 2.3. Determine: Research Design
  • 2.4. Prepare: Research Instrument
  • 2.5. Collect: Data Source
  • 2.6. Analyze: Data Interpretation
  • 2.7. Formulate: Data Verification
  • 2.8. Publish: Research Report
  • 2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer worldwide
      • 5.1.1.2. Growth in R&D activities and strong product pipeline
      • 5.1.1.3. Surging geriatric population base
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing cost of ADC
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in biopharma R&D
      • 5.1.3.2. Positive prospect in low market penetration nations
    • 5.1.4. Challenges
      • 5.1.4.1. Challenges related to downstream processing of Antibody Drug Conjugate
  • 5.2. Cumulative Impact of COVID-19

6. Antibody Drug Conjugate Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. CD30 Antibodies
  • 6.3. HER2 Antibodies

7. Antibody Drug Conjugate Market, by Drugs

  • 7.1. Introduction
  • 7.2. Adcetris
  • 7.3. Kadcyla

8. Antibody Drug Conjugate Market, by Technology

  • 8.1. Introduction
  • 8.2. Cleavable Linker
  • 8.3. Linkerless
  • 8.4. Non-cleavable Linker

9. Antibody Drug Conjugate Market, by Application

  • 9.1. Introduction
  • 9.2. Blood Cancer
  • 9.3. Breast Cancer
  • 9.4. Leukemia
  • 9.5. Lymphoma
  • 9.6. Multiple Myeloma
  • 9.7. Urothelial Cancer & Bladder Cancer

10. Antibody Drug Conjugate Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Research Institutes
  • 10.3. Biopharmaceutical Companies
  • 10.4. Biotechnology Companies
  • 10.5. Hospitals
  • 10.6. Others
  • 10.7. Specialized Cancer Centers

11. Americas Antibody Drug Conjugate Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antibody Drug Conjugate Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand

13. Europe, Middle East & Africa Antibody Drug Conjugate Market

  • 13.1. Introduction
  • 13.2. France
  • 13.3. Germany
  • 13.4. Italy
  • 13.5. Netherlands
  • 13.6. Qatar
  • 13.7. Russia
  • 13.8. Saudi Arabia
  • 13.9. South Africa
  • 13.10. Spain
  • 13.11. United Arab Emirates
  • 13.12. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
    • 14.1.1. Quadrants
    • 14.1.2. Business Strategy
    • 14.1.3. Product Satisfaction
  • 14.2. Market Ranking Analysis
  • 14.3. Market Share Analysis, By Key Player
  • 14.4. Competitive Scenario
    • 14.4.1. Merger & Acquisition
    • 14.4.2. Agreement, Collaboration, & Partnership
    • 14.4.3. New Product Launch & Enhancement
    • 14.4.4. Investment & Funding
    • 14.4.5. Award, Recognition, & Expansion

15. Company Usability Profiles

  • 15.1. Abbvie Inc.
  • 15.2. ADC Therapeutics
  • 15.3. Agensys, Inc.
  • 15.4. Astellas Pharma
  • 15.5. AstraZeneca
  • 15.6. Bayer AG
  • 15.7. Celldex Therapeutics Inc.
  • 15.8. Concortis Biotherapeutics
  • 15.9. Daiichi Sankyo Company Ltd.
  • 15.10. F. Hoffmann-La Roche Ltd.
  • 15.11. Gilead Sciences, Inc.
  • 15.12. GlaxoSmithKline Plc
  • 15.13. Immunomedics Inc.
  • 15.14. Novartis AG
  • 15.15. Oxford BioTherapeutics
  • 15.16. Pfizer, Inc.
  • 15.17. Sanofi S.A.
  • 15.18. Seagen, Inc.
  • 15.19. Seattle Genetics Inc.
  • 15.20. Synthon Holding B.V.
  • 15.21. Takeda Pharmaceutical Company Ltd.

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing
Back to Top
전화 문의
F A Q